<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266850</url>
  </required_header>
  <id_info>
    <org_study_id>08-0017</org_study_id>
    <secondary_id>N01AI80006C</secondary_id>
    <nct_id>NCT01266850</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules</brief_title>
  <official_title>Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules With RotaTeq® and Rotarix®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Rotavirus, sometimes called the &quot;stomach flu,&quot; is the most common cause of severe diarrhea in
      children. Vaccines can prevent many types of infections and work by causing the body to make
      proteins called antibodies that fight infection. For some vaccines, more than one vaccination
      is needed so that the body will make enough antibodies to fight infection. The vaccines
      (RotaTeq® or Rotarix® oral vaccines) given in this study are recommended for infants by the
      Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices
      (ACIP). These vaccines require either 2 or 3 vaccinations to be effective. Healthy infants
      between 6 weeks and 14 weeks, 6 days of age at Visit 1 will participate for about 10-12
      months. Study procedures include reaction assessment and blood sample.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rotavirus is the most common cause of severe gastroenteritis among children. The purpose of
      the proposed study is to determine the non-inferiority and safety of the 2 licensed rotavirus
      vaccines when both are administered to the same child during sequential vaccinations. Both
      Rotarix® and RotaTeq® vaccines have been evaluated for safety and efficacy in
      placebo-controlled trials with more than 70,000 infants each and it is likely that both
      vaccines delivered in various combinations will be safe and effective. Since RotaTeq® was
      licensed in the United States (US) in 2006, approximately 6 million doses have been
      administered in the US. In addition, Rotarix® has been licensed in over 100 nations worldwide
      and has been delivered to many children in Latin America where it has been recommended for
      universal vaccination for over 2 years. Now both RotaTeq® and Rotarix® are licensed in the
      US, and it is expected that health care providers will administer both vaccines. A 3-dose
      regimen is recommended for RotaTeq® and a 2-dose regimen for Rotarix®. From previous
      experience, it is likely that one of the vaccines may become unavailable for some period or
      pediatric offices may switch from one vaccine to the other. Thus, it is probable that mixed
      schedules will be administered to infants. The primary objective is to determine if the
      proportion of seroresponders in the sequential mixed rotavirus vaccine groups (RotaTeq® and
      Rotarix®) is non-inferior to the proportion of seroresponders in the recommended schedule of
      the single vaccine alone group. Secondary Objectives are: to determine the neutralizing
      rotavirus antibody responses to the most common rotavirus serotypes (G1-G4 and G9) at 3-6
      weeks after the last vaccination for both the sequential, mixed rotavirus vaccine schedule
      and the single rotavirus vaccine recommended schedule; and to determine if sequential mixed
      rotavirus vaccine schedules are safe with no statistically significant increase in fever,
      diarrhea, vomiting, or intussusception in the mixed schedule groups when compared with the
      recommended schedule of the single vaccine alone group. Normal healthy full-term infants who
      are scheduled to receive their routine infant immunizations and who are at least 6 weeks of
      age and no more than 14 weeks, 6 days of age at Visit 1 will be recruited from their primary
      care clinic. Infants will be randomized (open label) to one of 5 different rotavirus vaccine
      study groups. Two study groups will be administered the standard RotaTeq® or Rotarix®
      vaccines as 3 and 2 doses, respectively, and 3 study groups will be administered mixed
      sequences of RotaTeq® and Rotarix® given as 3 doses. All rotavirus vaccines will be
      administered concurrently with the other routinely administered childhood vaccines.
      Parents/legal guardians will be given a memory aid and a thermometer, and asked to record any
      suspected fever (with measured temperature documented) or adverse events for Days 1-8 after
      vaccination. At approximately 1 week after vaccination, study personnel will contact the
      parents/legal guardians, review the completed memory aid, and record the findings on the case
      report form. Blood for immunogenicity testing will be obtained 3-6 weeks after the last dose
      of vaccine. For the four 3-dose rotavirus vaccine study groups, blood will be obtained at
      approximately 7 months of age (3-6 weeks after the last rotavirus vaccine dose). For the
      single Rotarix® vaccine study group, blood will be obtained at approximately 5 months of age
      (3-6 weeks after the last dose of Rotarix® vaccine). The primary analysis will be based on
      rates of induction of anti-rotavirus serum immunoglobulin (Ig) A in the 5 study groups 3-6
      weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay</measure>
    <time_frame>3-6 weeks after the last vaccination</time_frame>
    <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the anti-rotavirus IgA antibody titer. A participant met the threshold of a positive response if the post vaccination anti-rotavirus IgA antibody titer was 20 or greater.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the 89-12 IgA Assay</measure>
    <time_frame>3-6 weeks after the last vaccination</time_frame>
    <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA 89-12 assay to determine the anti-rotavirus IgA antibody titer. A participant met the threshold of a positive response if the post vaccination anti-rotavirus IgA antibody titier was 20 or greater.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Serum Anti-rotavirus IgA Titer</measure>
    <time_frame>3-6 weeks after the last dose of vaccine</time_frame>
    <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the anti-rotavirus IgA antibody titers. The geometric mean titers (GMT) for each group were calculated along with the 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT of Neutralizing Rotavirus Antibody to the Most Common Rotavirus Serotypes (G1-G4 and G9)</measure>
    <time_frame>3-6 weeks after the last dose of vaccine.</time_frame>
    <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the neutralizing antibody assay against the most common rotavirus serotypes, G1-G4 and G9. Antigen-specific geometric mean titers (GMT) for each group were calculated along with the 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Solicited Systemic Reactions in the 8 Days After Vaccination</measure>
    <time_frame>Days 1-8 after each vaccination</time_frame>
    <description>The participants' parent/guardian was given a memory aid to record for 8 days the presence of solicited reactions of fever, diarrhea and vomiting. Fever was considered experienced if the participant was assessed with an axillary temperature of 100.4F or greater on any day in the 8-day period after any vaccination. Diarrhea was considered experienced if the participant had 3 or more looser than normal stools in a day. Vomiting was considered experienced if the participant vomited 2 or more times in a day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Hematochezia at Any Time During the Study</measure>
    <time_frame>Day 1 through 6 months after the last vaccination</time_frame>
    <description>Hematochezia was defined as any stools that are black and tarry; maroon in color; or frank red blood. At each visit, signs of hematochezia were assessed and the participant's parent/guardian was instructed to contact the clinical site at any time if the participant had evidence of hematochezia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Developing Neutralizing Rotavirus Antibody to Rotavirus Serotypes G1, G2, G4P6 and G9</measure>
    <time_frame>3-6 weeks after the last dose of vaccine.</time_frame>
    <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the antibody titers to rotavirus serotypes G1, G2, G4P6 and G9. A participant met the threshold of a positive response if the post vaccination antigen-specific antibody titer was 10 or greater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Developing Neutralizing Rotavirus Antibody to Rotavirus Serotype G3</measure>
    <time_frame>3-6 weeks after the last dose of vaccine.</time_frame>
    <description>Blood was collected from all participants prior to vaccination and at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the antibody titers to rotavirus serotype G3. A participant met the threshold of a positive response if the post vaccination antibody titer was 10 or greater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Developing Neutralizing Rotavirus Antibody to Rotavirus Serotypes G4P8</measure>
    <time_frame>3-6 weeks after the last dose of vaccine.</time_frame>
    <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the antibody titers to rotavirus serotype G4P8. A participant met the threshold of a positive response if the post vaccination antibody titer was 10 or greater.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1384</enrollment>
  <condition>Rotavirus Infection</condition>
  <arm_group>
    <arm_group_label>Group 1, RotaTeq® x 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2, 4 and 6 months of age: RotaTeq®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5, Rotarix®, RotaTeq® x2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 months of age: Rotarix®; 4 and 6 months of age: RotaTeq®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4, Rotarix® x 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 and 4 months of age: Rotarix®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2, RotaTeq®, Rotarix® x 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 months of age: RotaTeq®; 4 and 6 months of age: Rotarix®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3, RotaTeq® x 2, Rotarix®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 and 4 months of age: RotaTeq®; 6 months of age: Rotarix®</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotarix®</intervention_name>
    <description>Each 1-mL dose of Rotarix® contains a suspension of at least 10^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.</description>
    <arm_group_label>Group 2, RotaTeq®, Rotarix® x 2</arm_group_label>
    <arm_group_label>Group 3, RotaTeq® x 2, Rotarix®</arm_group_label>
    <arm_group_label>Group 4, Rotarix® x 2</arm_group_label>
    <arm_group_label>Group 5, Rotarix®, RotaTeq® x2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RotaTeq®</intervention_name>
    <description>2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.</description>
    <arm_group_label>Group 1, RotaTeq® x 3</arm_group_label>
    <arm_group_label>Group 2, RotaTeq®, Rotarix® x 2</arm_group_label>
    <arm_group_label>Group 3, RotaTeq® x 2, Rotarix®</arm_group_label>
    <arm_group_label>Group 5, Rotarix®, RotaTeq® x2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female infants who are at least 6 weeks of age and no more than 14 weeks, 6
             days of age at Visit 1.

          -  Parent(s)/legal guardian(s) have signed informed consent documents.

          -  Children who will be available for the entire study period and whose parents/legal
             guardians can be reached by telephone.

          -  Healthy infants as determined by medical history and by a baseline physical
             examination with no clinically significant abnormal findings within 14 days before the
             first dose.

          -  Parents/legal guardians able to complete all relevant study procedures during study
             participation.

        Exclusion Criteria:

          -  Any clinically significant history of gastrointestinal disease including abdominal
             surgery or liver disease or other serious medical conditions as determined by the site
             investigator.

          -  Any history of immunodeficiency in the infant (e.g., the infant is known to be human
             immunodeficiency virus (HIV) positive, to have hypogammaglobulinemia, or to have an
             underlying malignancy), or any infant with any unvaccinated household contact who is
             immunocompromised such as:

               -  Any malignancies or are otherwise immunocompromised;

               -  Primary immunodeficiency; or

               -  Receiving immunosuppressive therapy.

          -  Known sensitivity to any vaccine components, such as latex in the Rotarix® applicator.

          -  Previous receipt of a rotavirus vaccine.

          -  Acute illness at the time of vaccine administration, such as any of the following
             within the past 48 hours:

               1. Axillary temperature of 100.4 degrees Fahrenheit or higher, or

               2. More than 3 grossly watery stools, or

               3. Any episodes of vomiting (forceful expulsion of partially digested milk/food).
                  Infants with previous diagnoses of gastroesophageal reflux whose regurgitation
                  episodes have not changed in the 48-hour period prior to the first vaccination
                  may be enrolled.

        If these symptoms clear within 48 hours and the subject meets the other inclusion/exclusion
        criteria, then the subject may be enrolled.

          -  The subject is currently participating in a study that involves an experimental agent
             (vaccine, drug, biologic, device, blood product, or medication) or has received an
             experimental agent within 1 month prior to enrollment in this study, or expects to
             receive another experimental agent during participation in this study.

          -  Less than 37 weeks gestation at birth.

          -  Receipt of blood and/or blood products (including immunoglobulin) within 4 weeks
             before vaccine administration.

          -  Receipt of live vaccine within the past 30 days or a nonreplicating, inactivated, or
             subunit vaccine within the last 14 days, although planned licensed trivalent
             inactivated influenza vaccine that may be administered to children over 6 months of
             age during a routine clinic visit is permitted and would not be exclusionary.

          -  The subject has any condition that would, in the opinion of the site investigator,
             place the subject at an unacceptable risk of injury or render the subject unable to
             meet the requirements of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>14 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kaiser Permanente Vaccine Study Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612-3610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center Oakland - Primary Care Clinic</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94618-1033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Children's Center - Pediatric Infectious Diseases</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-1014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa - Vaccine Research &amp; Education Unit</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-2600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine - Center for Vaccine Development - Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital and Clinics - Infectious Diseases</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108-4619</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Translational Medicine Institute - Clinical Vaccine Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704-2120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Physicians Research Inc. - Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241-3100</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical Branch - Sealy Center for Vaccine Development (SCVD)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-1121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Molecular Virology and Microbiology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Health Research Institute - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101-1466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital - Infectious Diseases</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105-3901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <results_first_submitted>October 9, 2014</results_first_submitted>
  <results_first_submitted_qc>October 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2014</results_first_posted>
  <last_update_submitted>October 23, 2014</last_update_submitted>
  <last_update_submitted_qc>October 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine, rotavirus, gastroenteritis, infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were healthy males and females age 6-14 weeks, recruited from the communities at large around the clinical sites. Participants were enrolled and vaccinated between 24MAR2011 and 08APR2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: RotaTeq, RotaTeq, RotaTeq</title>
          <description>Participants received RotaTeq® orally at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: RotaTeq, Rotarix, Rotarix</title>
          <description>Participants received RotaTeq® orally at 2 months of age, followed by Rotarix® orally at 4 and 6 months of age.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: RotaTeq, RotaTeq, Rotarix</title>
          <description>Participants received RotaTeq® orally at 2 and 4 months of age, followed by Rotarix® orally at 6 months of age.</description>
        </group>
        <group group_id="P4">
          <title>Group 4: Rotarix, Rotarix</title>
          <description>Participants received Rotarix® orally at 2 and 4 months of age.</description>
        </group>
        <group group_id="P5">
          <title>Group 5: Rotarix, RotaTeq, RotaTeq</title>
          <description>Participants received Rotarix® orally at 2 months of age, followed by RotaTeq® orally at 4 and 6 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="242"/>
                <participants group_id="P2" count="248"/>
                <participants group_id="P3" count="238"/>
                <participants group_id="P4" count="329"/>
                <participants group_id="P5" count="327"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Second Vaccine</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="233"/>
                <participants group_id="P3" count="227"/>
                <participants group_id="P4" count="311"/>
                <participants group_id="P5" count="307"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Third Vaccine</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
                <participants group_id="P2" count="221"/>
                <participants group_id="P3" count="217"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="299"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="212"/>
                <participants group_id="P3" count="214"/>
                <participants group_id="P4" count="301"/>
                <participants group_id="P5" count="297"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Population for baseline analysis includes all participants who were enrolled, randomized, and received at least the first vaccination.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: RotaTeq, RotaTeq, RotaTeq</title>
          <description>Participants received 2-mL RotaTeq® orally at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: RotaTeq, Rotarix, Rotarix</title>
          <description>Participants received 2-mL RotaTeq® orally at 2 months of age, followed by 1-mL Rotarix® orally at 4 and 6 months of age.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: RotaTeq, RotaTeq, Rotarix</title>
          <description>Participants received 2-mL RotaTeq® orally at 2 and 4 months of age, followed by 1-mL Rotarix® orally at 6 months of age.</description>
        </group>
        <group group_id="B4">
          <title>Group 4: Rotarix, Rotarix</title>
          <description>Participants received 2-mL Rotarix® orally at 2 and 4 months of age.</description>
        </group>
        <group group_id="B5">
          <title>Group 5: Rotarix, RotaTeq, RotaTeq</title>
          <description>Participants received 2-mL Rotarix® orally at 2 months of age, followed by 1-mL RotaTeq® orally at 4 and 6 months of age.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="242"/>
            <count group_id="B2" value="248"/>
            <count group_id="B3" value="238"/>
            <count group_id="B4" value="329"/>
            <count group_id="B5" value="327"/>
            <count group_id="B6" value="1384"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.2" spread="1.4"/>
                    <measurement group_id="B2" value="9.1" spread="1.2"/>
                    <measurement group_id="B3" value="9.2" spread="1.2"/>
                    <measurement group_id="B4" value="9.1" spread="1.2"/>
                    <measurement group_id="B5" value="9.2" spread="1.4"/>
                    <measurement group_id="B6" value="9.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="248"/>
                    <measurement group_id="B3" value="238"/>
                    <measurement group_id="B4" value="329"/>
                    <measurement group_id="B5" value="327"/>
                    <measurement group_id="B6" value="1384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="176"/>
                    <measurement group_id="B5" value="149"/>
                    <measurement group_id="B6" value="686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="153"/>
                    <measurement group_id="B5" value="178"/>
                    <measurement group_id="B6" value="698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="81"/>
                    <measurement group_id="B6" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="139"/>
                    <measurement group_id="B4" value="199"/>
                    <measurement group_id="B5" value="195"/>
                    <measurement group_id="B6" value="819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="67"/>
                    <measurement group_id="B6" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="193"/>
                    <measurement group_id="B4" value="277"/>
                    <measurement group_id="B5" value="260"/>
                    <measurement group_id="B6" value="1130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="248"/>
                    <measurement group_id="B3" value="238"/>
                    <measurement group_id="B4" value="329"/>
                    <measurement group_id="B5" value="327"/>
                    <measurement group_id="B6" value="1384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay</title>
        <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the anti-rotavirus IgA antibody titer. A participant met the threshold of a positive response if the post vaccination anti-rotavirus IgA antibody titer was 20 or greater.</description>
        <time_frame>3-6 weeks after the last vaccination</time_frame>
        <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: RotaTeq, RotaTeq, RotaTeq</title>
            <description>Participants received RotaTeq® orally at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: RotaTeq, Rotarix, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 months of age, followed by Rotarix® orally at 4 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: RotaTeq, RotaTeq, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 and 4 months of age, followed by Rotarix® orally at 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Rotarix, Rotarix</title>
            <description>Participants received Rotarix® orally at 2 and 4 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Rotarix, RotaTeq, RotaTeq</title>
            <description>Participants received Rotarix® orally at 2 months of age, followed by RotaTeq® orally at 4 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay</title>
          <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the anti-rotavirus IgA antibody titer. A participant met the threshold of a positive response if the post vaccination anti-rotavirus IgA antibody titer was 20 or greater.</description>
          <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="194"/>
                <count group_id="O4" value="287"/>
                <count group_id="O5" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="182"/>
                    <measurement group_id="O3" value="175"/>
                    <measurement group_id="O4" value="191"/>
                    <measurement group_id="O5" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the 89-12 IgA Assay</title>
        <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA 89-12 assay to determine the anti-rotavirus IgA antibody titer. A participant met the threshold of a positive response if the post vaccination anti-rotavirus IgA antibody titier was 20 or greater.</description>
        <time_frame>3-6 weeks after the last vaccination</time_frame>
        <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: RotaTeq, RotaTeq, RotaTeq</title>
            <description>Participants received RotaTeq® orally at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: RotaTeq, Rotarix, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 months of age, followed by Rotarix® orally at 4 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: RotaTeq, RotaTeq, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 and 4 months of age, followed by Rotarix® orally at 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Rotarix, Rotarix</title>
            <description>Participants received Rotarix® orally at 2 and 4 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Rotarix, RotaTeq, RotaTeq</title>
            <description>Participants received Rotarix® orally at 2 months of age, followed by RotaTeq® orally at 4 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the 89-12 IgA Assay</title>
          <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA 89-12 assay to determine the anti-rotavirus IgA antibody titer. A participant met the threshold of a positive response if the post vaccination anti-rotavirus IgA antibody titier was 20 or greater.</description>
          <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="193"/>
                <count group_id="O4" value="287"/>
                <count group_id="O5" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="184"/>
                    <measurement group_id="O3" value="165"/>
                    <measurement group_id="O4" value="219"/>
                    <measurement group_id="O5" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT of Neutralizing Rotavirus Antibody to the Most Common Rotavirus Serotypes (G1-G4 and G9)</title>
        <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the neutralizing antibody assay against the most common rotavirus serotypes, G1-G4 and G9. Antigen-specific geometric mean titers (GMT) for each group were calculated along with the 95% confidence intervals.</description>
        <time_frame>3-6 weeks after the last dose of vaccine.</time_frame>
        <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: RotaTeq, RotaTeq, RotaTeq</title>
            <description>Participants received RotaTeq® orally at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: RotaTeq, Rotarix, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 months of age, followed by Rotarix® orally at 4 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: RotaTeq, RotaTeq, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 and 4 months of age, followed by Rotarix® orally at 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Rotarix, Rotarix</title>
            <description>Participants received Rotarix® orally at 2 and 4 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Rotarix, RotaTeq, RotaTeq</title>
            <description>Participants received Rotarix® orally at 2 months of age, followed by RotaTeq® orally at 4 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT of Neutralizing Rotavirus Antibody to the Most Common Rotavirus Serotypes (G1-G4 and G9)</title>
          <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the neutralizing antibody assay against the most common rotavirus serotypes, G1-G4 and G9. Antigen-specific geometric mean titers (GMT) for each group were calculated along with the 95% confidence intervals.</description>
          <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
          <units>titers</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="195"/>
                <count group_id="O4" value="287"/>
                <count group_id="O5" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G1P[8] Antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" lower_limit="68.81" upper_limit="103.72"/>
                    <measurement group_id="O2" value="93.6" lower_limit="76.88" upper_limit="114.02"/>
                    <measurement group_id="O3" value="112.0" lower_limit="89.68" upper_limit="139.84"/>
                    <measurement group_id="O4" value="45.3" lower_limit="39.60" upper_limit="51.75"/>
                    <measurement group_id="O5" value="96.6" lower_limit="81.73" upper_limit="114.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2P[4] Antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="14.54" upper_limit="20.11"/>
                    <measurement group_id="O2" value="14.5" lower_limit="12.33" upper_limit="17.02"/>
                    <measurement group_id="O3" value="17.5" lower_limit="14.68" upper_limit="20.94"/>
                    <measurement group_id="O4" value="7.1" lower_limit="6.51" upper_limit="7.76"/>
                    <measurement group_id="O5" value="19.3" lower_limit="16.50" upper_limit="22.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3,P[8] Antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="11.06" upper_limit="15.01"/>
                    <measurement group_id="O2" value="16.8" lower_limit="14.40" upper_limit="19.61"/>
                    <measurement group_id="O3" value="16.6" lower_limit="13.91" upper_limit="19.83"/>
                    <measurement group_id="O4" value="14.0" lower_limit="12.50" upper_limit="15.65"/>
                    <measurement group_id="O5" value="22.2" lower_limit="18.89" upper_limit="25.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G4P[6] Antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="16.08" upper_limit="21.63"/>
                    <measurement group_id="O2" value="17.7" lower_limit="15.18" upper_limit="20.74"/>
                    <measurement group_id="O3" value="21.3" lower_limit="17.92" upper_limit="25.21"/>
                    <measurement group_id="O4" value="7.0" lower_limit="6.49" upper_limit="7.59"/>
                    <measurement group_id="O5" value="19.0" lower_limit="16.58" upper_limit="21.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G4P[8] Antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="22.17" upper_limit="30.67"/>
                    <measurement group_id="O2" value="22.1" lower_limit="18.77" upper_limit="26.01"/>
                    <measurement group_id="O3" value="24.9" lower_limit="21.22" upper_limit="29.28"/>
                    <measurement group_id="O4" value="8.7" lower_limit="7.96" upper_limit="9.58"/>
                    <measurement group_id="O5" value="25.6" lower_limit="22.28" upper_limit="29.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G9P[6] Antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="11.24" upper_limit="15.38"/>
                    <measurement group_id="O2" value="13.5" lower_limit="11.58" upper_limit="15.75"/>
                    <measurement group_id="O3" value="16.1" lower_limit="13.37" upper_limit="19.37"/>
                    <measurement group_id="O4" value="6.8" lower_limit="6.37" upper_limit="7.34"/>
                    <measurement group_id="O5" value="14.5" lower_limit="12.57" upper_limit="16.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Solicited Systemic Reactions in the 8 Days After Vaccination</title>
        <description>The participants' parent/guardian was given a memory aid to record for 8 days the presence of solicited reactions of fever, diarrhea and vomiting. Fever was considered experienced if the participant was assessed with an axillary temperature of 100.4F or greater on any day in the 8-day period after any vaccination. Diarrhea was considered experienced if the participant had 3 or more looser than normal stools in a day. Vomiting was considered experienced if the participant vomited 2 or more times in a day.</description>
        <time_frame>Days 1-8 after each vaccination</time_frame>
        <population>All participants who were vaccinated and had reactogenicity data reported are included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: RotaTeq, RotaTeq, RotaTeq</title>
            <description>Participants received RotaTeq® orally at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: RotaTeq, Rotarix, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 months of age, followed by Rotarix® orally at 4 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: RotaTeq, RotaTeq, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 and 4 months of age, followed by Rotarix® orally at 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Rotarix, Rotarix</title>
            <description>Participants received Rotarix® orally at 2 and 4 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Rotarix, RotaTeq, RotaTeq</title>
            <description>Participants received Rotarix® orally at 2 months of age, followed by RotaTeq® orally at 4 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Solicited Systemic Reactions in the 8 Days After Vaccination</title>
          <description>The participants' parent/guardian was given a memory aid to record for 8 days the presence of solicited reactions of fever, diarrhea and vomiting. Fever was considered experienced if the participant was assessed with an axillary temperature of 100.4F or greater on any day in the 8-day period after any vaccination. Diarrhea was considered experienced if the participant had 3 or more looser than normal stools in a day. Vomiting was considered experienced if the participant vomited 2 or more times in a day.</description>
          <population>All participants who were vaccinated and had reactogenicity data reported are included in the analysis population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="326"/>
                <count group_id="O5" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Hematochezia at Any Time During the Study</title>
        <description>Hematochezia was defined as any stools that are black and tarry; maroon in color; or frank red blood. At each visit, signs of hematochezia were assessed and the participant's parent/guardian was instructed to contact the clinical site at any time if the participant had evidence of hematochezia.</description>
        <time_frame>Day 1 through 6 months after the last vaccination</time_frame>
        <population>All participants who were vaccinated are included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: RotaTeq, RotaTeq, RotaTeq</title>
            <description>Participants received RotaTeq® orally at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: RotaTeq, Rotarix, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 months of age, followed by Rotarix® orally at 4 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: RotaTeq, RotaTeq, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 and 4 months of age, followed by Rotarix® orally at 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Rotarix, Rotarix</title>
            <description>Participants received Rotarix® orally at 2 and 4 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Rotarix, RotaTeq, RotaTeq</title>
            <description>Participants received Rotarix® orally at 2 months of age, followed by RotaTeq® orally at 4 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Hematochezia at Any Time During the Study</title>
          <description>Hematochezia was defined as any stools that are black and tarry; maroon in color; or frank red blood. At each visit, signs of hematochezia were assessed and the participant's parent/guardian was instructed to contact the clinical site at any time if the participant had evidence of hematochezia.</description>
          <population>All participants who were vaccinated are included in the analysis population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="326"/>
                <count group_id="O5" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Serum Anti-rotavirus IgA Titer</title>
        <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the anti-rotavirus IgA antibody titers. The geometric mean titers (GMT) for each group were calculated along with the 95% confidence intervals.</description>
        <time_frame>3-6 weeks after the last dose of vaccine</time_frame>
        <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: RotaTeq, RotaTeq, RotaTeq</title>
            <description>Participants received RotaTeq® orally at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: RotaTeq, Rotarix, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 months of age, followed by Rotarix® orally at 4 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: RotaTeq, RotaTeq, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 and 4 months of age, followed by Rotarix® orally at 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Rotarix, Rotarix</title>
            <description>Participants received Rotarix® orally at 2 and 4 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Rotarix, RotaTeq, RotaTeq</title>
            <description>Participants received Rotarix® orally at 2 months of age, followed by RotaTeq® orally at 4 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Serum Anti-rotavirus IgA Titer</title>
          <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the anti-rotavirus IgA antibody titers. The geometric mean titers (GMT) for each group were calculated along with the 95% confidence intervals.</description>
          <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
          <units>titers</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="195"/>
                <count group_id="O4" value="287"/>
                <count group_id="O5" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WC3 Assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.03" lower_limit="231.519" upper_limit="373.407"/>
                    <measurement group_id="O2" value="215.81" lower_limit="168.355" upper_limit="276.652"/>
                    <measurement group_id="O3" value="305.89" lower_limit="238.614" upper_limit="392.130"/>
                    <measurement group_id="O4" value="38.06" lower_limit="31.715" upper_limit="45.685"/>
                    <measurement group_id="O5" value="256.90" lower_limit="214.441" upper_limit="307.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>89-12 Assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.89" lower_limit="49.355" upper_limit="75.121"/>
                    <measurement group_id="O2" value="115.72" lower_limit="94.543" upper_limit="141.642"/>
                    <measurement group_id="O3" value="104.04" lower_limit="83.026" upper_limit="130.383"/>
                    <measurement group_id="O4" value="100.21" lower_limit="80.582" upper_limit="124.629"/>
                    <measurement group_id="O5" value="212.52" lower_limit="173.815" upper_limit="259.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Developing Neutralizing Rotavirus Antibody to Rotavirus Serotypes G1, G2, G4P6 and G9</title>
        <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the antibody titers to rotavirus serotypes G1, G2, G4P6 and G9. A participant met the threshold of a positive response if the post vaccination antigen-specific antibody titer was 10 or greater.</description>
        <time_frame>3-6 weeks after the last dose of vaccine.</time_frame>
        <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: RotaTeq, RotaTeq, RotaTeq</title>
            <description>Participants received RotaTeq® orally at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: RotaTeq, Rotarix, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 months of age, followed by Rotarix® orally at 4 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: RotaTeq, RotaTeq, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 and 4 months of age, followed by Rotarix® orally at 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Rotarix, Rotarix</title>
            <description>Participants received Rotarix® orally at 2 and 4 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Rotarix, RotaTeq, RotaTeq</title>
            <description>Participants received Rotarix® orally at 2 months of age, followed by RotaTeq® orally at 4 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing Neutralizing Rotavirus Antibody to Rotavirus Serotypes G1, G2, G4P6 and G9</title>
          <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the antibody titers to rotavirus serotypes G1, G2, G4P6 and G9. A participant met the threshold of a positive response if the post vaccination antigen-specific antibody titer was 10 or greater.</description>
          <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="194"/>
                <count group_id="O4" value="287"/>
                <count group_id="O5" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G1P[8] Antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="192"/>
                    <measurement group_id="O3" value="176"/>
                    <measurement group_id="O4" value="260"/>
                    <measurement group_id="O5" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2P[4] Antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="116"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G4P[6] Antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="145"/>
                    <measurement group_id="O4" value="68"/>
                    <measurement group_id="O5" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G9P[6] Antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="71"/>
                    <measurement group_id="O5" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Developing Neutralizing Rotavirus Antibody to Rotavirus Serotype G3</title>
        <description>Blood was collected from all participants prior to vaccination and at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the antibody titers to rotavirus serotype G3. A participant met the threshold of a positive response if the post vaccination antibody titer was 10 or greater.</description>
        <time_frame>3-6 weeks after the last dose of vaccine.</time_frame>
        <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: RotaTeq, RotaTeq, RotaTeq</title>
            <description>Participants received RotaTeq® orally at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: RotaTeq, Rotarix, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 months of age, followed by Rotarix® orally at 4 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: RotaTeq, RotaTeq, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 and 4 months of age, followed by Rotarix® orally at 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Rotarix, Rotarix</title>
            <description>Participants received Rotarix® orally at 2 and 4 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Rotarix, RotaTeq, RotaTeq</title>
            <description>Participants received Rotarix® orally at 2 months of age, followed by RotaTeq® orally at 4 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing Neutralizing Rotavirus Antibody to Rotavirus Serotype G3</title>
          <description>Blood was collected from all participants prior to vaccination and at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the antibody titers to rotavirus serotype G3. A participant met the threshold of a positive response if the post vaccination antibody titer was 10 or greater.</description>
          <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="194"/>
                <count group_id="O4" value="287"/>
                <count group_id="O5" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="134"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="179"/>
                    <measurement group_id="O5" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Developing Neutralizing Rotavirus Antibody to Rotavirus Serotypes G4P8</title>
        <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the antibody titers to rotavirus serotype G4P8. A participant met the threshold of a positive response if the post vaccination antibody titer was 10 or greater.</description>
        <time_frame>3-6 weeks after the last dose of vaccine.</time_frame>
        <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: RotaTeq, RotaTeq, RotaTeq</title>
            <description>Participants received RotaTeq® orally at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: RotaTeq, Rotarix, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 months of age, followed by Rotarix® orally at 4 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: RotaTeq, RotaTeq, Rotarix</title>
            <description>Participants received RotaTeq® orally at 2 and 4 months of age, followed by Rotarix® orally at 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Rotarix, Rotarix</title>
            <description>Participants received Rotarix® orally at 2 and 4 months of age.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Rotarix, RotaTeq, RotaTeq</title>
            <description>Participants received Rotarix® orally at 2 months of age, followed by RotaTeq® orally at 4 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing Neutralizing Rotavirus Antibody to Rotavirus Serotypes G4P8</title>
          <description>Blood was collected from all participants at the follow up visit 3-6 weeks after the last vaccination for testing in the ELISA assay to determine the antibody titers to rotavirus serotype G4P8. A participant met the threshold of a positive response if the post vaccination antibody titer was 10 or greater.</description>
          <population>The per protocol analysis population includes participants who met all inclusion and exclusion criteria, received all scheduled study vaccinations, and who contributed post-vaccination blood samples for testing for which valid results were reported.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="190"/>
                <count group_id="O4" value="287"/>
                <count group_id="O5" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="150"/>
                    <measurement group_id="O4" value="114"/>
                    <measurement group_id="O5" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited and unsolicited adverse events were collected for 8 days after each vaccination. Serious adverse events were collected from the first vaccination through the last follow-up visit at 6 months after the last vaccination.</time_frame>
      <desc>For events solicited on the memory aid in the 8 days after each vaccination, a participant was considered to have one event if it was reported as experienced at any time in the 8-day period. Each 8-day period was considered a separate event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: RotaTeq, RotaTeq, RotaTeq</title>
          <description>Participants received RotaTeq® orally at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: RotaTeq, Rotarix, Rotarix</title>
          <description>Participants received RotaTeq® orally at 2 months of age, followed by Rotarix® orally at 4 and 6 months of age.</description>
        </group>
        <group group_id="E3">
          <title>Group 3: RotaTeq, RotaTeq, Rotarix</title>
          <description>Participants received RotaTeq® orally at 2 and 4 months of age, followed by Rotarix® orally at 6 months of age.</description>
        </group>
        <group group_id="E4">
          <title>Group 4: Rotarix, Rotarix</title>
          <description>Participants received Rotarix® orally at 2 and 4 months of age.</description>
        </group>
        <group group_id="E5">
          <title>Group 5: Rotarix, RotaTeq, RotaTeq</title>
          <description>Participants received Rotarix® orally at 2 months of age, followed by RotaTeq® orally at 4 and 6 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="248"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Craniosynostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="248"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Eczema herpeticum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Vulval cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Gross motor delay</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apparent life threatening event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="248"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="329"/>
                <counts group_id="E5" subjects_affected="135" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="44" subjects_affected="35" subjects_at_risk="242"/>
                <counts group_id="E2" events="54" subjects_affected="38" subjects_at_risk="248"/>
                <counts group_id="E3" events="51" subjects_affected="40" subjects_at_risk="238"/>
                <counts group_id="E4" events="70" subjects_affected="53" subjects_at_risk="329"/>
                <counts group_id="E5" events="90" subjects_affected="61" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="248"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="238"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="329"/>
                <counts group_id="E5" events="13" subjects_affected="12" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="248"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="238"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E5" events="15" subjects_affected="13" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="242"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="248"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="329"/>
                <counts group_id="E5" events="29" subjects_affected="27" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="242"/>
                <counts group_id="E2" events="44" subjects_affected="38" subjects_at_risk="248"/>
                <counts group_id="E3" events="34" subjects_affected="31" subjects_at_risk="238"/>
                <counts group_id="E4" events="24" subjects_affected="24" subjects_at_risk="329"/>
                <counts group_id="E5" events="61" subjects_affected="50" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="242"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="248"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="238"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="329"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathryn M. Edwards, MD</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>615-322-3078</phone>
      <email>kathryn.edwards@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

